Suffolk Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Suffolk Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$367K	Sell	4,335 -1,199	-22%	-$128K	0.07%	89
2018 Q3	$948K	Sell	5,534 -1,367	-20%	-$206K	0.13%	66
2018 Q2	$892K	Sell	6,901 -575	-8%	-$64.2K	0.13%	75
2018 Q1	$770K	Sell	7,476 -5,771	-44%	-$571K	0.11%	101
2017 Q4	$1.13M	Buy	13,247 +3,823	+41%	+$331K	0.15%	58
2017 Q3	$800K	Sell	9,424 -12,500	-57%	-$990K	0.11%	107
2017 Q2	$1.66M	Buy	21,924 +3,044	+16%	+$213K	0.22%	78
2017 Q1	$1.25M	Sell	18,880 -1,856	-9%	-$122K	0.17%	111
2016 Q4	$1.31M	Sell	20,736 -4,202	-17%	-$265K	0.18%	112
2016 Q3	$1.59M	Sell	24,938 -7,855	-24%	-$577K	0.22%	82
2016 Q2	$2.44M	Buy	32,793 +9,498	+41%	+$705K	0.31%	94
2016 Q1	$1.56M	Sell	23,295 -11,262	-33%	-$684K	0.21%	129
2015 Q4	$2.34M	Sell	34,557 -10,713	-24%	-$661K	0.3%	106
2015 Q3	$2.42M	Buy	45,270 +5,886	+15%	+$357K	0.32%	93
2015 Q2	$2.48M	Sell	39,384 -28,713	-42%	-$1.57M	0.29%	110
2015 Q1	$3.28M	Sell	68,097 -17,922	-21%	-$687K	0.38%	71
2014 Q4	$2.85M	Buy	86,019 +32,639	+61%	+$1.06M	0.35%	94
2014 Q3	$1.56M	Sell	53,380 -16,030	-23%	-$532K	0.19%	127
2014 Q2	$2.7M	Buy	69,410 +25,327	+57%	+$1.03M	0.33%	100
2014 Q1	$1.85M	Buy	+44,083	New	+$1.84M	0.23%	124

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Suffolk Capital Management's LGND Position: Q4 2018 in Review

Suffolk Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 22% in Q4 2018, selling an estimated $128K and leaving 4,335 shares worth $367K. The position accounts for 0.07% of the portfolio, ranked #89.

Suffolk Capital Management first reported a position in LGND in Q1 2014 and has held it in 20 quarters since. The position peaked at $3.28M in Q1 2015. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

Suffolk Capital Management held 4,335 shares of Ligand Pharmaceuticals worth $367K as of Q4 2018.
Suffolk Capital Management sold 1,199 Ligand Pharmaceuticals shares in Q4 2018, an estimated $128K.
Ligand Pharmaceuticals made up 0.07% of Suffolk Capital Management's portfolio in Q4 2018, its #89 holding.
Suffolk Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2014 and has held it in 20 quarters since.
Suffolk Capital Management's Ligand Pharmaceuticals position peaked at $3.28M in Q1 2015.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Suffolk Capital Management's 13F filing for Q4 2018, filed 23 Jan 2019.